"BPC-157 vs TB-500." "Ipa vs CJC-1295." "Sema vs tirz." Those queries pull thousands of searches a month, and the top results are almost always written by vendors with skin in the game. The "independent" pieces aren't much better, mostly thin editorial without the structured data you actually need.
A real peptide comparison is multi-dimensional. Mechanism beats marketing copy every time. Half-life decides your dosing calendar. Human trial count separates the well-studied from the speculative. Cost per mcg matters once you're running a long cycle. The Next Pep comparison tool at /compare puts all of that side-by-side, free, no signup, 60+ peptides. This article is the framework we built it on.
Key Takeaways
- —Most peptide comparison content online is vendor-authored — price and benefits framed in the vendor's favour.
- —A mechanism-aligned comparison uses six dimensions: receptor target, pharmacokinetics, evidence depth, safety profile, dosing schedule, and regulatory status.
- —Human trial count is the single most-underweighted data point in typical peptide comparisons — BPC-157 has 1 qualifying human study across a 30-year literature, yet is often compared to GLP-1 agonists that have tens of thousands of trial subjects.
- —The Next Pep comparison tool pulls molecular, pharmacological, and regulatory data into one side-by-side view; vendor data is excluded from the comparison layer by design.
- —Free, browser-based, up to 4 peptides side-by-side.
Lead with the things that don't predict outcomes. Three traps people fall into when they're new to vetting compounds:
Get those out of the way first. Then move to the dimensions that actually matter.
The peptide research industry is mostly vendor-owned media. Vendors write the "BPC-157 vs TB-500" pieces that rank in the top 10 for those queries. It's not always dishonest — a vendor's content can be well-researched — but the bias is structural. Articles that recommend a compound the author sells outperform articles that recommend something a competitor stocks.
Three failure modes that show up in vendor-written comparisons:
What's usually missing: the table structure that makes a fair comparison possible. Both peptides, the same dimensions, the same data density per cell.
A mechanism-aligned comparison covers six dimensions. The data is in the public literature; most comparison content never assembles it.
The most important dimension, because it determines whether two peptides are substitutes or complements. BPC-157 and TB-500 both accelerate tissue repair in preclinical models, but they hit different receptor systems (angiogenic cascades vs G-actin binding). They're not substitutes — they're complements (the Wolverine stack runs both for exactly that reason). Tirzepatide and semaglutide are both incretin-mimetics, but tirz adds GIP receptor agonism on top of GLP-1 — it's a mechanistic superset of sema.
The practical question this dimension answers: can I swap one peptide for the other and get a similar outcome? Substitutes: yes. Complements: no.
How long the peptide stays in circulation determines dosing frequency. BPC-157's plasma half-life is 15 minutes in rat IV; CJC-1295 DAC's is 6–8 days via albumin binding. Both end up in healing or GH-axis protocols, but the dosing calendar differs by orders of magnitude.
Route matters too. BPC-157 is oral-stable (gastric-acid resistant, viable for GI applications); most peptides aren't. Most comparison content glosses over route availability entirely.
The question isn't "is there evidence" — it's "how much, in whom, and how recent?"
BPC-157 has ~35 preclinical studies and 1 human study (per the 2025 AAOS systematic review). Tirzepatide has tens of thousands of Phase III patient-years (SURMOUNT, SURPASS trials). You can put them on the same comparison axis — but the evidence tier weighs more than the headline efficacy stat.
Preclinical safety and human safety are different datasets. Most research peptides have strong preclinical safety records and thin human safety data. Comparison content often blurs them. A fair safety comparison breaks out: species in which safety was established, dose range tested, duration, and any reported adverse events.
Weekly vs daily pinning is a major practical variable. So is route (subq vs oral), titration requirement (GLP-1s need slow titration; most research peptides don't), and whether the protocol's cyclical (4–8 weeks on, 2–4 weeks off for most research peptides) or continuous.
FDA status (approved drug vs Category 1/2 compoundable vs research-compound vs prohibited), WADA status (banned in sport or not), and realistic cost per mcg at current market pricing. Domestic vs international sourcing factors in here too — domestic ships in 2–4 days and dodges customs; international is half the price but expect 2–3 weeks and the occasional seizure letter. Context variables that determine feasibility, not efficacy.
The Next Pep comparison engine at /compare pulls all six dimensions into one side-by-side view, free, no signup. Up to 4 peptides at a time. For any peptide already in the research library — BPC-157, TB-500, Tirzepatide, Semaglutide, Ipamorelin, CJC-1295, Sermorelin, GHK-Cu, PT-141, Epitalon, MOTS-c, NAD+, Semax, Selank, Thymosin Alpha-1, and 45+ others — the data is pre-loaded.
What the tool shows side-by-side:
No sponsorship layer. No affiliate manipulation of the comparison order. The comparison surface is built from primary data, not from what generates a commission.
Each of these loads both peptides into the comparison view in one click:
A comparison tool answers "what are the measurable differences between these compounds?" It doesn't answer "which one should I use?" That depends on:
The comparison layer narrows the decision space. The decision itself is still yours, ideally with licensed professional input for anything clinical.
Six dimensions: receptor target/mechanism, pharmacokinetics, evidence depth (especially human trial count), safety profile, dosing schedule, and regulatory status. Vendor-authored content typically covers one or two and markets the rest. A structured comparison covers all six and makes the data density per dimension obvious.
Yes, /compare is fully free, no signup, runs in any browser. Up to 4 peptides side-by-side. The 60+ compounds in our library are pre-loaded with full molecular and pharmacological data.
Editorial independence. The moment a comparison tool has a commercial interest in one outcome over another, users should distrust it. Next Pep is a research platform — we don't sell peptides and we don't take affiliate commissions from vendors that influence our comparison display order.
Paste any vendor product URL into the library search bar. Our URL-import extractor pulls the peptide's name, mechanism, sequence, and molecular data from the vendor page in 20–40 seconds and adds it to the library. From there you can compare it against anything else.
Molecular and mechanism data comes from PubChem, UniProt, and PubMed. Dosing protocols come from published clinical/research literature. We update the library monthly for compounds with active literature and on-demand when new trial data publishes.
This article is for research and informational purposes only. The compounds compared are, in most cases, not FDA-approved for human clinical use. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.